Home | Welcome to Contract Pharma   
Last Updated Friday, September 19 2014
Print

Financial Report: AMRI



Published February 12, 2013
Related Searches: Manufacturing Development
AMRI

4Q Revenues: $67.2 million (+44%)

4Q Earnings: $1.9 million (loss of $24.4 million in 4Q11)

FY Revenues: $226.7 million (+9%)

FY Loss: $3.8 million (loss of $32.3 million FY11)

Comments: Contract revenue in the quarter was $59.1 million, up 50%. Development/Small Scale Manufacturing revenue was $10.4 million, up 41%. Large Scale Manufacturing revenue was $38.1 million, up 69%. Discovery Services revenue was $10.6 million, up 12%. Royalty revenue in the quarter was $8.1 million, up 13%. Loss in 4Q11 was related to charges associated with the company's closure of its Bothell, WA facility. FY12 loss includes asset impairment charges of $6.7 million and restructuring charges of approximately $4.2 million related to the company's realignment of its global Discovery Services platform.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On